Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulcrum Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulcrum Therapeutics's regulatory disclosures and financial reporting.
Fulcrum Therapeutics (NASDAQ:FULC) filed a Form 8-K reporting the results of its 26 June 2025 annual stockholder meeting.
- Shareholders elected Katina Dorton, Robert Gould and Kate Haviland as Class III directors for terms ending in 2028.
- The non-binding say-on-pay proposal passed with 46.1 million votes for, 0.11 million against and 8.3 thousand abstentions.
- Investors recommended an annual frequency for future say-on-pay votes (44.9 million votes for one year).
- Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 49.5 million votes for and no broker non-votes.
No other material corporate actions or operational changes were disclosed.